CA Patent

CA2464995A1 — Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene

Assigned to Novartis AG · Expires 2003-05-08 · 23y expired

What this patent protects

This invention relates to the use of the novel association between the 483 A >G single nucleotide polymorphism of the TCF1 gene and the clinical response to glycemic control agents, such as DPPIV inhibitors, in patients with disorder s of glycemic control, especially diabetes …

USPTO Abstract

This invention relates to the use of the novel association between the 483 A >G single nucleotide polymorphism of the TCF1 gene and the clinical response to glycemic control agents, such as DPPIV inhibitors, in patients with disorder s of glycemic control, especially diabetes and impaired glucose metabolism. Th is invention provides methods to classify patients for treatment and/or for optimization of clinical studies and to treat patients based on this association.

Drugs covered by this patent

Patent Metadata

Patent number
CA2464995A1
Jurisdiction
CA
Classification
—
Expires
2003-05-08
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.